{
    "nct_id": "NCT03444714",
    "official_title": "Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors",
    "inclusion_criteria": "* Diagnosis of advanced or metastatic cancer not amenable to curative therapy\n* Lesion that is amenable to palliative radiotherapy\n* Lesion that is technically feasible to irradiation and accessible for direct intratumoral injection\n* Target tumor in region not in previously irradiated field\n* Patient must have recovered from acute toxic effects (â‰¤ grade 1) of previous cancer treatments prior to enrollment\n* Age >18 years\n* Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion\n* Females with child bearing age should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to the start of dosing\n* Patients must sign a study-specific informed consent form prior to study entry\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with a histological diagnosis of lymphomas and/or leukemias\n* Patients may not have received chemotherapy, targeted therapies, biologic response modifiers and/or hormonal therapy within the last 14 days\n* Ongoing clinically significant infection at or near the incident lesion\n* Major surgery over the target area (excluding placement of vascular access) <21 days from beginning of the study drug or minor surgical procedures <7 days\n* Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study\n* Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial\n* Pregnant and nursing women\n* Patients with a target lesion located in a previously irradiated field",
    "miscellaneous_criteria": ""
}